News
M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021
– Preclinical data provide proof of concept for recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) demonstrating improved mannose 6-phosphorylation – – Leveraging the Company’s proprietary S1S3 bicistronic expression ...
Read More →
M6P Therapeutics Announces Presentation at the Upcoming 16th International Symposium of MPS and Related Diseases
– Oral Presentation on Friday, July 23, 2021 @ 11:25 a.m. ET / 17:25 p.m. CEST – ST. LOUIS, Mo., – July 21, 2021 – ...
Read More →
M6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage Disorders
– Webinar on Wednesday, July 28 @ 10 a.m. ET – ST. LOUIS, Mo., – July 19, 2021 – M6P Therapeutics (“M6PT” or “the Company”), ...
Read More →
M6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum
– Discussion to include progress and innovations in next-generation therapies for the treatment of lysosomal storage disorders – ST. LOUIS, Mo., – June 25, 2021 ...
Read More →
M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting
– Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type ...
Read More →
M6P Therapeutics Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
St. LOUIS, Mo., – April 28, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal ...
Read More →